(Q37649587)

21 August 2017

1 reference

title

Emerging targeted therapies for bladder cancer: a disease waiting for a drug (English)

1 reference

21 August 2017

1 reference

Simon J Dovedi

1

1 reference

PubMed ID

19997963

21 August 2017

Barry R Davies

series ordinal

2

1 reference

21 August 2017

1 December 2009

1 reference

Cancer and Metastasis Reviews

21 August 2017

1 reference

21 August 2017

28

1 reference

21 August 2017

355-367

1 reference

21 August 2017

3-4

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-009-9192-9

21 August 2017

0 references

cites work

Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions

1 reference

https://api.crossref.org/works/10.1007%2FS10555-009-9192-9

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-009-9192-9

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-009-9192-9

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-009-9192-9

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-009-9192-9

Targeting EGFR in bladder cancer

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1007/S00345-007-0202-7

Identifiers

DOI

10.1007/S10555-009-9192-9

1 reference

21 August 2017

1 reference

PubMed ID

19997963